|
|
Prepublished online as a Blood First Edition Paper on October 10, 2002; DOI 10.1182/blood-2002-02-0620.
 Previous Article | Table of Contents | Next Article 
Blood, 15 February 2003, Vol. 101, No. 4, pp. 1419-1421
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Brief report
Platelet activation induced by human antibodies to
interleukin-8
Véronique Regnault,
Emmanuel de Maistre,
Jean-Pierre Carteaux,
Yves Gruel,
Philippe Nguyen,
Brigitte Tardy, and
Thomas Lecompte
From Hématologie, Faculté de
Médecine, Nancy, France; Service
d'Hématologie Biologique et Clinique de Chirurgie
Cardio-vasculaire et Transplantation du Centre Hospitalier
Universitaire (CHU) de Nancy, France; Service
d'Hématologie-Hémostase du CHU A. Trousseau de Tours,
France; EA 2070, Faculté de Médecine de Reims,
France; Département d'Hématologie du CHU de
Saint Etienne, France.
Some cases of heparin-induced thrombocytopenia (HIT) have been
reported to be associated with antibodies against interleukin-8 (IL-8),
a chemokine related to platelet factor 4. We found that sera from 5 HIT
patients containing immunoglobulin G (IgG) or IgM antibodies to IL-8,
as evidenced using surface plasmon resonance spectroscopy, were able to
trigger IL-8-dependent activation of washed platelets, leading to
procoagulant activity. This activation occurred at IL-8 concentrations
achievable in vivo and was facilitated by heparin (0.1 U/mL).
Activation was also induced by affinity-purified anti-IL-8 IgG and
involved Fc RIIa. In the 2 patients who could be followed up,
antibodies were no longer detectable 4 months after heparin withdrawal.
One additional patient with paraneoplastic recurrent thrombosis without
thrombocytopenia was found to have platelet-activating anti-IL-8 IgM,
but in this case heparin was inhibitory. This is another example
of potentially pathogenic platelet activation by antibodies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Shantsila, G. Y. H. Lip, and B. H. Chong
Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management
Chest,
June 1, 2009;
135(6):
1651 - 1664.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Mullen, D. L. Wessel, K. C. Thomas, K. Gauvreau, E. J. Neufeld, F. X. McGowan Jr, and J. A. DiNardo
The Incidence and Implications of Anti-Heparin-Platelet Factor 4 Antibody Formation in a Pediatric Cardiac Surgical Population
Anesth. Analg.,
August 1, 2008;
107(2):
371 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Membre, D. Wahl, V. Latger-Cannard, J.-P. Max, P. Lacolley, T. Lecompte, and V. Regnault
The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies
Haematologica,
April 1, 2008;
93(4):
566 - 573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Al-Mohanna, S. Saleh, R. S. Parhar, K. Khabar, and K. Collison
Human neutrophil gene expression profiling following xenogeneic encounter with porcine aortic endothelial cells: the occult role of neutrophils in xenograft rejection revealed
J. Leukoc. Biol.,
July 1, 2005;
78(1):
51 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
